ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 984

Reduced Expression of CX3CR1 in Peripheral CD14++CD16+monocytes Is a Novel Feature of Patients with Systemic Lupus Erythematosus

Keiko Yoshimoto1, Katsuya Suzuki1, Shuntaro Saito2, Jun Kikuchi1 and Tsutomu Takeuchi1, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Chemokine Receptors, SLE and monocytes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Cytokines and Cell Trafficking Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Fractalkine (FKN, CX3CL1) and its receptor, CX3CR1, play an important role in chemotaxis of immune cells, such as cell adhesion, migration and infiltration into the organs. Several lines of evidence indicated that serum level of FKN was elevated and correlated with disease activity in patients with rheumatoid arthritis (RA) and the expression of CX3CR1 is upregulated especially in peripheral intermediate monocytes, CD14++CD16+in RA patients as compared to healthy controls (HC). On the other hand, it has been reported that elevated expression CX3CR1+macrophages were infiltrated in the kidney of lupus patients and CD16+monocytes within the glomerular blood vessels of the patients corresponds to the high CX3CR1+expressing monocytes. In this study, we investigated the expression level of CX3CR1 in peripheral monocytes and T cells from patients with systemic lupus erythematosus (SLE) and HC to elucidate the possible involvement of CX3CR1 in immunological features of SLE.

Methods: The expression level of CX3CR1 in peripheral monocytes (classical monocytes: CD14++CD16–, intermediate monocytes: CD14++CD16+, non-classical monocytes: CD14+CD16++), CD4 and CD8 T cells was analyzed by FACS with whole blood samples from patients with SLE active (SLEDAI : >10, n = 22), inactive (SLEDAI: <4, n = 22) and HC (n = 34).Differences between the groups were examined for statistical significance using the t test for single comparisons. Correl correlation analysis was employed for evaluation of the linear relationship between two continuous variables.

Results: FACS analysis revealed that the proportion of CD14++CD16+monocytes among CD14+ cells was significantly elevated in SLE active (p = 0.0017) and SLE inactive (p = 0.0002) patients as compared to HC, whereas no significant difference was observed in that proportion between SLE active and inactive patients. Notably, the proportion of CX3CR1 positive cells in CD14++CD16+monocytes was significantly lower in SLE active patients than patients with SLE inactive (p = 0.014) and HC (p = 0.002), whereas that proportion was not significantly different between SLE inactive and HC. In addition, the proportion of CX3CR1 positive cells in CD4 and CD8 T cells was not significantly different among the groups.

Conclusion: These results give the possibility that FKN binds its receptor, CX3CR1, expressed on CD14++CD16+monocytes in SLE, and the cells consequently migrate into the organs through peripheral blood. Our data suggest that targeting FKN signaling may be effective for suppressing inflammatory monocyte recruitment to the organs in SLE.


Disclosure: K. Yoshimoto, None; K. Suzuki, None; S. Saito, None; J. Kikuchi, None; T. Takeuchi, None.

To cite this abstract in AMA style:

Yoshimoto K, Suzuki K, Saito S, Kikuchi J, Takeuchi T. Reduced Expression of CX3CR1 in Peripheral CD14++CD16+monocytes Is a Novel Feature of Patients with Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/reduced-expression-of-cx3cr1-in-peripheral-cd14cd16monocytes-is-a-novel-feature-of-patients-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reduced-expression-of-cx3cr1-in-peripheral-cd14cd16monocytes-is-a-novel-feature-of-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology